Investment Q&A

Q: of the 3 companies on your new feature chart watcher, he was most pisitive on agf, but you do not seem to like it, it keeps hitting 52 week highs, could you comment. dave

Q: Echelon-EFH. You last provided info on this company May 19, 2016 and I wondered if your opinion has changed. Things look better at the company, volume have been in the high side. Do you think this company might put themselves up for sale or be a takeover candidate?
Thank you.

Q: How do earnings look?

Q: Could you please rank the following US banks based on valuation in a rising rate environment
And what's your thoughts on the US raising rates going forward until December 2018. How many rate rises do you see by that time
Thank you
Kevin

Q: I have a position in Visa. Analyzing the historical chart I can see that this stock just doesn't seem to go down. The only extended pull back since 2009 that I can see was in 2014 and it basically went sideways for about 10 months. Since than it has grown at least 25%/year. The yield is small, but with this kind of growth it doesn't really matter. Also, the use of Visa will only expand as tech companies fight for transaction fees, and with inflation their revenues can only go up. It seems to me only an extended recession can effect their growth. For these reasons wouldn't Visa be a good place to go "overweight"?

Q: Greetings 5i,

I currently hold positions (slightly more than a half position each) in both TD and BNS (TD for their American exposure and BNS for their international exposure). In your opinion, is it necessary to own two Canadian banks? Do they complement each other well, or is there too much redundancy? If the latter, would you recommend one over the other?

I have a long term horizon (I am 35), am fairly conservative, and prefer long-term holds. In the Canadian financial sector, I also hold SLF and BAM.A.

Thank you.

Q: Hi Team,
Would you kindly comment on Fairfax's announced sale of Singaporean insurer First Capital Insurance Ltd. for US $1.6B and it's ongoing strategic alliance with Japan’s Mitsui Sumitomo Insurance Co. Do you have any thoughts about how significant this deal is and how it will improve Fairfax's prospects for the future?
Thank you, Michael

Q: CM reported good results today similar to RY's yesterday--beat expected eps by 0.11,increase domestic banking(by 8%),mortgage volume(12%) & US wealth management(76%) with decline in provision for loan losses,but capital market decline 10%.Please help me to understand why it dropped 2% today after an initial spike of some $1.19.Thanks for u usual great services & views.Is this a good entry point?

Q: do you think either of these is a buy now?

Q: This rather small company appears to have a sound balance sheet, and has growing profits. Just hit its 52 week high. Any interest in this business lender?

Q: Do you recommend this stock for investment?
At what price would this be a good buy?
Is the monthly dividend sustainable?

Q: Manulife Class-action has a settlement amount of $69,000,000 to be distributed among shareholders past and present April 1, 2004 to October 9, 2017). It has 2 billion shares outstanding. I have 350 shares which I have held for five months. Since the shares are in insurance company, pension fund, ETF and mutual fund portfolios, is it worth filing a claim. I predict a payout of less than $10 (if any) as many shares have been sold in the 13 year time lapse.

Q: Is BNS still your top can.bank pick?How will the currencies of its international exposure affects its earnings?The recent appreciation of the can$ against US$ will likely have a negative impact for those banks with US exposure eg TD ,BMO & RY

Q: The outlook for this company.
Buy , Sell . or ,Hold

Q: Thoughts on FSZ earnings and valuation?

Considering starting a position in my income portfolio, but FSZ seems to be rangebound the past few years between 12-14. Would it be better just to stick to bank stocks for the financial sector as the banks have a lower beta and better capital appreciation, which more than makes up for the 1% greater yield of FSZ?

Q: May I have your opinion on their recent earnings report, and your opinion on this company as an investment?

Q: Hi 5i! Regarding Callidus (CBL), can you comment on the implications of their ongoing share repurchases given the recent share price decline and the relatively tight float? With their FY 2016 Report, CBL indicated “49,916,781 common shares comprising Callidus' total issued and outstanding.” At the same time, they announced an NCIB allowing repurchase of up to 5 percent of that total (i.e. 2,495,839 of its common shares). In the Q2 2017 Report CBL indicated that approximately 1.26M shares had been repurchased under the 2017 NCIB through August 9. All repurchased shares are being cancelled. My online broker’s site currently indicates the number of floating shares at 9.11M. With such a small percentage of issued and outstanding shares floating, a full repurchase under the NCIB would appear to reduce the float by approximately 25 percent. Is it safe to assume that only floating shares are being taken up under the NCIB? As the share float dwindles, does an ultimate privatization become all the more likely? Are there any specific advantages or dangers associated with the shrinking number of floating shares, particularly in connection with a potential privatization and as far as retail shareholders may be concerned? Thanks for any insights!

Q: Is there any specific reason for the further 7% drop in the stock price of Callidus today? Thanks.

Q: Any thoughts on the recent results from Equitable Group? Despite what initially appear to be strong earnings reported Thursday p.m., the stock was down significantly in Friday trading. Thank-you.

Q: Please give me your updated opinion on Keycorp vs the larger US banks. I appreciate your help.